Comparative Pharmacology
Head-to-head clinical analysis: AZO GANTANOL versus MYTREX F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZO GANTANOL versus MYTREX F.
AZO GANTANOL vs MYTREX F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenazopyridine is an azo dye with local analgesic effect on urinary tract mucosa via unknown mechanism; sulfamethoxazole is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folate synthesis.
Methylprednisolone is a corticosteroid that inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell activity.
AZO GANTANOL (phenazopyridine + sulfamethoxazole) is not a standard combination product. Assuming separate components: Sulfamethoxazole 800 mg and Trimethoprim 160 mg (as Bactrim DS) orally every 12 hours. For phenazopyridine: 200 mg orally three times daily after meals.
Oral methotrexate 7.5-25 mg once weekly; subcutaneous methotrexate 7.5-25 mg once weekly; intravenous methotrexate 50-200 mg/m² every 2-3 weeks for oncology indications.
None Documented
None Documented
Sulfamethoxazole terminal half-life: 9-12 hours in adults with normal renal function (CrCl >80 mL/min); prolonged to 20-50 hours in CKD (CrCl <30 mL/min); phenazopyridine half-life: 9-11 hours
3.5 hours (terminal); prolonged to 8-12 hours in renal impairment.
Renal: 70% as sulfamethoxazole (30% acetylated), N5-acetylated metabolite accounts for 15%; fecal: 20% of dose excreted unchanged in bile; biliary: minor contribution (<5%)
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic